- Report
- March 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- March 2025
- 175 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 129 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Clinical Trials
- December 2024
- 550 Pages
Global
From €4551EUR$5,000USD£3,901GBP
- Report
- August 2024
- 150 Pages
Global
From €2538EUR$2,789USD£2,176GBP
- Report
- August 2022
- 285 Pages
Global
From €8646EUR$9,500USD£7,412GBP
- Report
- February 2024
- 204 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- August 2018
- 48 Pages
Global
From €9101EUR$10,000USD£7,802GBP
Abraxane is a chemotherapy drug used to treat non-small cell lung cancer (NSCLC). It is a nanoparticle albumin-bound (nab) paclitaxel, a type of chemotherapy drug that is delivered directly to the tumor cells. Abraxane is used in combination with other drugs to treat NSCLC, and is often used in combination with carboplatin or cisplatin. Abraxane has been shown to be more effective than traditional paclitaxel in treating NSCLC, and has fewer side effects. Abraxane is also used to treat other types of cancer, including breast, ovarian, and pancreatic cancer.
The Abraxane market is highly competitive, with several companies offering similar products. Some of the major players in the market include Celgene Corporation, Bristol-Myers Squibb, Pfizer, and Merck & Co. Other companies in the market include AstraZeneca, Novartis, and Eli Lilly. Show Less Read more
